Compare VANI & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VANI | MDCX |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.2M | 53.4M |
| IPO Year | 2014 | N/A |
| Metric | VANI | MDCX |
|---|---|---|
| Price | $1.35 | $1.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $23.50 |
| AVG Volume (30 Days) | 195.1K | ★ 365.5K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $1.49 |
| 52 Week High | $1.92 | $8.94 |
| Indicator | VANI | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 34.31 |
| Support Level | $1.36 | $1.49 |
| Resistance Level | $1.46 | $2.03 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 4.00 | 7.89 |
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.